ReciBioPharm, a division of Recipharm, a CDMO, has been awarded a three-year grant from the Bill & Melinda Gates Foundation to support the global deployment of xRNA Continuous Manufacturing technologies to Low- and Middle-Income Countries with a focus on the development of inline Process Analytical Technologies and predictive analytics software. ReciBioPharm’s platform aims to improve the scalability, quality, and accessibility of RNA-based medicines and will help advance its goal of developing fully integrated, continuous processes.

Vikas Gupta, President of ReciBioPharm, said: “This grant represents a significant milestone in our commitment to advancing RNA manufacturing technologies that meet FDA standards. We are proud to lead this transformative effort, expanding access to RNA-based solutions for underserved regions.”

“Our previously-announced collaboration with MIT has underscored the potential of continuous manufacturing for RNA therapeutics,” added Aaron Cowley, Chief Scientific Officer of ReciBioPharm. “This grant will help to strengthen our role as a pioneer in innovation and support our mission to make lifesaving technologies more accessible.”